Vilprafen

Vilprafen – an antibiotic of group of macroleads of bactericidal action.

Form of release and structure

Vilprafen produce in the form of tablets, film coated – biconvex, oblong, almost white or white color, with risks on both sides (10 pieces in blisters, on 1 blister in a cardboard pack).

Active agent джозамицин, in number of 500 mg is a part of 1 tablet.

Auxiliary components in 1 tablet: polysorbate of 80 - 5 mg; magnesium stearate – 5 mg; microcrystallic cellulose – 101 mg; colloid silicon dioxide – 14 mg; a karmelloza of sodium – 10 mg.

Structure of a cover: polyethyleneglycol of 6000 - 0,3846 mg; methyl cellulose – 0,12825 mg; titanium dioxide – 0,641 mg; talc – 2,0513 mg; copolymer of methacrylic acid and its ethers – 1,15385 mg; aluminum hydroxide – 0,641 mg.

Indications to use

Vilprafen appoint for treatment of the infectious and inflammatory diseases caused by microorganisms, sensitive to effect of active agent (dzhozamitsin):

• Infections of lower parts of respiratory tracts – an acute bronchitis, whooping cough, bronchial pneumonia, a psittacosis, pneumonia, including an atypical form;
• Infections of ENT organs and upper parts of respiratory tracts – sinusitis, tonsillitis, a peritonsillitis, pharyngitis, average otitis, laryngitis;
• Oral cavity infections – diseases of a parodont and an ulitis;
• Scarlet fever (at hypersensitivity to penicillin);
• Diphtheria (in addition to therapy by diphtheritic antitoxin);
• Infections of generative organs and urinary tract – prostatitis, an urethritis, gonorrhea; at hypersensitivity to penicillin – a venereal lymphogranuloma, syphilis;
• Mycoplasmal (including ureaplazmenny), Chlamidia and multi-infections of generative organs and urinary tract;
• Infections of soft tissues and skin – lymphadenitis, a lymphangitis, furuncles, a pyoderma, eels, a malignant anthrax, an erysipelatous inflammation (at hypersensitivity to penicillin).

Contraindications

• Heavy functional disturbances of a liver;
• Hypersensitivity to components of drug and other antibiotics of group of macroleads.

The feeding and pregnant women can accept Vilprafen only in cases when the expected advantage for health of mother exceeds possible risk for a fruit or the child.

Route of administration and dosage

Vilprafen accept inside between meals. The tablet should be swallowed entirely and to wash down with a small amount of water.

For teenagers aged from 14 years and adults the recommended daily dose makes 1-2 g of Vilprafen which needs to be divided into 2-3 receptions. The initial recommended dose – 1 g.

At spherical and ordinary eels within the first 2-4 weeks appoint 2 times a day 0,5 g of a dzhozamitsin, further within 2 months reduce the frequency of use to 0,5 g of a dzhozamitsin of 1 time a day (as a maintenance therapy).

Treatment duration usually is defined by the doctor. According to recommendations of World Health Organization about use of antibiotic drugs, duration of therapy of streptococcal infections has to be not less than 10 days.

If one reception of Vilprafen is missed, it is necessary to accept a dose immediately. In cases if time of the following administration of drug came, it is not necessary to increase a dose.

Having rummaged in therapy or premature phase-out of drug reduce probability of success of treatment.

Side effects

During Vilprafen's reception development of disturbances from various systems of an organism is possible:

• Digestive tract: seldom – heartburn, nausea, appetite loss, diarrhea and vomiting. At heavy persistent diarrhea it must be kept in mind a possibility of development of the pseudomembranous colitis (posing hazard to life), caused by action of an antibiotic;
• Hearing aid: in rare instances – a dozozavisimy passing hearing disorder;
• Biliary tract and liver: in some cases – the tranzitorny increase in activity of liver enzymes in a blood plasma sometimes accompanied with jaundice and disturbance of outflow of bile;
• Hypersensitivity reactions: in some cases – skin allergic reactions (for example, a small tortoiseshell).

Special instructions

At development of pseudomembranous colitis Vilprafen it is necessary to cancel and appoint the corresponding treatment. It is contraindicated to accept the drugs reducing motility of intestines.

Patients with a renal failure need to adjust the dosing mode according to values of the clearance of creatinine (CC).

To premature children Vilprafen do not appoint. At use for newborns it is necessary to control function of a liver.

It is necessary to consider a possibility of cross stability to various antibiotic drugs of group of macroleads.

Medicinal interaction

It is necessary to avoid simultaneous use of Vilprafen with cephalosporins and penicillin.

At combined use with lincomycin decrease in efficiency of both drugs is possible.

Vilprafen to a lesser extent slows down theophylline removal, than other antibiotic drugs of group of macroleads.

At simultaneous use with cyclosporine increase in its concentration in a blood plasma is possible up to nephrotoxic.

There are messages on strengthening of vasopressor action at combined use of alkaloids of an ergot of antibiotics and drugs of group of macroleads.

Vilprafen slows down removal of an astemizol or terfenadin that increases risk of development of life-threatening arrhythmias.

At simultaneous use with digoxin increase in level of the last in a blood plasma is possible.

At simultaneous use of drug with hormonal contraceptives it is in addition necessary to use non-hormonal contraceptives.

Terms and storage conditions

To store in protected from light, the place, unavailable to children, at a temperature up to 25 °C.

Period of validity – 4 years.